The 3 best ASX travel stocks according to Stocks Down Under
Marc Kennis, August 11, 2023
The trend of “revenge travel” isn’t slowing down, despite predictions of a downturn. Quite the contrary, travel now forms a significant portion of household budgets, showing up prominently in company share prices and market performance.
Our own Stuart Roberts says travel expenditures continue to constitute a crucial part of household budgets. He emphasizes the ongoing prosperity in the travel sector, using Airbnb’s latest figures as evidence. This data indicates an 11% YoY growth, demonstrating the industry’s resilience.
What are the Best ASX Travel stocks to invest in right now?
Check our buy/sell tips on the top ASX Travel stocks
As for the future of travel, Stuart looks toward potential stars like Flight Center (ASX:FLT) and SiteMinder (ASX:SDR), who are making waves in the industry. Additionally, he introduces Jayride (ASX:JAY) – a global aggregator for ride services linking airports with hotels, which Stuart perceives as a potential game-changer.
In spite of the pandemic’s challenges, he suggests numerous companies may still benefit from the ‘revenge travel’ trend. Stuart urges us to overlook negative conjecture around the financial health of the travel industry, alluding to the ongoing success seen in various companies’ share prices as counter evidence.
CHECK OUT STUART’S INTERVIEW ON AUSBIZ BELOW!
Stuart Roberts talking about the best ASX travel stocks on AusBiz
Blog Categories
Get Our Top 5 ASX Stocks for FY26
Recent Posts
Channel Infrastructure NZ (ASX:CHI): Another Kiwi company just joined the ASX, but this one is the nation’s largest fuel supplier
Last Friday, Channel Infrastructure NZ listed on the ASX as a dual-listing. It is unlike the bulk of Kiwi companies…
Arafura Rare Earths (ASX:ARU) Nears FID With $1.35 Billion Secured- Time to Buy?
Arafura Rare Earths (ASX: ARU) presents one of the most puzzling setups on the ASX right now. The company has…
Mesoblast (ASX:MSB) Reaches Multi-Year High as Ryoncil Revenue Targets US$30M: Is It Still a Buy?
Commercial momentum builds as Mesoblast targets two major 2026 catalysts: Adult label expansion and Revascor BLA filing. Mesoblast (ASX: MSB)…
